Short answer
Relay Therapeutics, Inc. (RLAY) filed an 8-K current report with the SEC on May 19, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Initial Phase 2 ReInspire data for zovegalisib in vascular anomalies disclosed on May 19, 2026.
Relay Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Initial Phase 2 ReInspire data for zovegalisib in vascular anomalies disclosed on May 19, 2026
- Clinical update accompanied by investor conference call and live webcast
- Exhibit 99.1 contains the press release; Exhibit 99.2 contains presentation slides
- Data represent a key clinical catalyst for zovegalisib’s development and investor assessment of the program
Item 8.01 · Other Events
- Phase 2 ReInspire data: 60% volumetric response among 20 evaluable patients with PIK3CA-driven vascular anomalies
- Responses included PROS and lymphatic malformations, supporting potential activity across mutation types and disease subgroups
- Response durability signal: all four patients with 24-week scans maintained responses with deeper lesion reductions
- Favorable tolerability at 100mg and 300mg BID: 9% Grade 3+ treatment-related adverse events and no discontinuations
- 400mg BID deprioritized for suboptimal tolerability, concentrating dose optimization on lower doses for chronic treatment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Relay Therapeutics, Inc. 8-K filings
Get the next RLAY 8-K as it lands
Follow RLAY for push alerts, or ask the research agent what this filing means.